Endologix announced today that it appointed Mike Mathias as its new chief commercial officer (CCO), effective immediately.
Mathias brings 30 years of experience leading commercial organizations within the cardiovascular area. He most recently served as VP of commercial operations at Limflow. He held that role from 2022 until Inari Medical acquired the chronic limb-threatening ischemia (CLTI) treatment maker last year.
At Endologix, his role includes overseeing commercial operations for the artery disease treatment developer.
“Joining Endologix at such a critical juncture is an honor,” Mathias said in a news release. “I am excited to apply my experience to innovate and join the leadership team of a company that stands at the forefront of interventional vascular therapies. Together, we will work to enhance our commercial strategy, ensuring success for our commercial teams and the organization as a whole.”
Before LimFlow, Mathias spent 20 years in various commercial leadership roles at Medtronic. He led Medtronic’s U.S. commercial operations for heart valve therapies, launching its transcatheter aortic valve replacement (TAVR) technology.
“We are delighted to bring such an experienced and successful leader into Endologix,” said Endologix President and CEO Dr. Matt Thompson. “Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans. His extensive experience and success in launching pioneering therapies in the medical device industry make him an invaluable asset to our senior leadership team. We believe that with Mike’s leadership, our global sales, business development, and marketing teams will continue to thrive.”
